David Bautz joined Zacks as a Biotechnology Analyst in February 2014. Prior to joining Zacks, David was an NRSA postdoctoral fellow investigating the genetics of colorectal cancer morphology. During his tenure as a postdoctoral fellow David also conducted research developing active immunotherapies and monoclonal antibodies as potential treatments for colorectal cancer.

David obtained his PhD in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill in 2008. His dissertation research focused on the characterization of autoantibodies in patients suffering from an orphan autoimmune disease.

Prior to obtaining his PhD, David worked for two years as a research associate at Human Genome Sciences, Inc., a biotechnology company that was eventually acquired by GlaxoSmithKline.

David obtained his BS and MS degrees in Biochemistry from Virginia Tech.